Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Food Effect, Single-Dose Proportionality, and Multiple-Dose Pharmacokinetic Comparison With Melogabalin Besilate Tablets After Single and Multiple Oral Administrations of BM2216 Extended-Release Tablets in Healthy Adult Subjects.--Single-Center, Randomized, Open-Label, Parallel/Crossover Design.
Conditions
Interventions
BM2216 Extended-Release tablets（5.5mg）
Mirogabalin Besilate Tablets
+2 more
Locations
1
China
Chongqing Bishan People's Hospital
Chongqing, Chongqing Municipality, China
Start Date
December 1, 2024
Primary Completion Date
January 4, 2025
Completion Date
January 12, 2025
Last Updated
February 27, 2025
NCT07224321
NCT07260656
NCT07232537
NCT06513026
NCT07536516
NCT07340320
Lead Sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions